What Caused The NanoVibronix (NAOV) Stock To Rise In Extended Trades?

Following the release of preliminary findings from clinical research, NanoVibronix Inc. (NASD: NAOV) saw a 10.07% increase at $0.2755 in after-hours trading hours on the most recent check Tuesday.

What research findings have NAOV disclosed?

Last week, NanoVibronix (NAOV) released the preliminary findings of the UroShield clinical trial being carried out in the United Kingdom by The University of Southampton and the National Biofilms Innovation Centre.

Top 5 AI Stocks to Buy for 2023

The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything. According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.

Click Here to Download the FREE Report.


The NanoVibronix team was encouraged by the preliminary findings of the quantitative and qualitative UroShield research conducted in Southampton. The outcomes are encouraging and represent a critical next step in NAOV’s development into the UK market, obtaining the FDA’s permanent authorization, and increasing manufacturing for U.S. distribution. When the research is released in 2023, NAOV will receive further details.

The independent, real-world patient study’s first findings point to changes in the variety of the microbial community after usage of the Uroshield, with possible positive impacts on the microbiome of the urine and catheter systems. In addition to these studies, the majority of patients who used the Uroshield reported fewer infections and catheter obstructions, among other favorable outcomes.

In order to close a gap in the Company’s clinical data and create the documentation needed by the FDA for a permanent 510K clearance, NAOV started the research in April 2021. Microbiological investigations of urine and catheter samples taken before and after the use of the Uroshield device were performed as part of the preliminary clinical research utilizing a mix of culture, microscopy, and sequencing methods.

NAOV provided a business update

Additionally, last week, Brian Murphy, the chief executive officer of NAOV, sent a letter to the company’s shareholders with a business update. NAOV promised to increase its sales by bringing on more foreign distribution partners. In order to help it find appropriate distributors and perhaps even private label partners for the distribution of its UroShield product, NAOV is now in talks with a partner on a European basis.

What did NAOV say regarding operations?

The majority of NanoVibronix’s third-party manufacturing processes have now been moved to Singapore, the company said in an update, and it got its first finished product in September. By moving its manufacture to Singapore, NAOV is less vulnerable to supply shortages and geopolitical volatility and is better positioned to grow its production and boost throughput as necessary.

Most Popular

Related Posts